The National Institute for Health and Care Excellence (NICE) has announced that EYLEA (aflibercept solution for intravitreal injection, known in the scientific literature as VEGF Trap-Eye).
Should be recommended as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). When guidance is finalised NHS bodies will have 90 days to ensure EYLEA is made available to all eligible patients.
MMM has been operating worldwide as one of the leading system providers in the service of health since 1954. With a full portfolio of products and services pertaining to sterilization & disinfection systems for hospitals, scientific institutes, laboratories & the pharmaceutical industry, MMM has positioned itself as a crucial quality driver.
Hilton Birmingham Metropole Hotel
26th - 27th November 2024
Birmingham Conference & Events Centre (BCEC)
Wednesday 4th December 2024
TBA, Leeds
7th December 2024
Kia Oval, London
11th March 2025, 9:00am - 4:00pm
The National Conference Centre, Birmingham
29th – 30th April 2025
The National Conference Centre, Birmingham
11th April 2025
